Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx™)

This publication has 6 references indexed in Scilit:

• Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2
  Rheumatology, 1999
• The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor
  Bioorganic & Medicinal Chemistry Letters, 1999
• Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis
  Proceedings of the National Academy of Sciences, 1999
• Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model
  Clinical Pharmacology & Therapeutics, 1999
• Rofecoxib
  Drugs of the Future, 1998
• Integrated Application of Capillary HPLC/Continuous-Flow Liquid Secondary Ion Mass Spectrometry to Discovery Stage Metabolism Studies
  Analytical Chemistry, 1995